Finanzen von Repligen Corp (RGEN)RGENRepligen Corp

Repligen Corporation (RGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue - Filtration products, accounting for 47.7% of total sales, equivalent to $28.88M. Other significant revenue streams include Product revenu - Protein products and Product revenue-Chromatography products. Understanding this composition is critical for investors evaluating how RGEN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Repligen Corporation maintains a gross margin of 53.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.60%, while the net margin is 2.45%. These profitability ratios, combined with a Return on Equity (ROE) of 1.99%, provide a clear picture of how effectively RGEN converts its operational activities into shareholder value.

In the context of the broader market, RGEN competes directly with industry leaders such as CYTK and IONS. With a market capitalization of $9.42B, it holds a significant position in the sector. When comparing efficiency, RGEN's gross margin of 53.91% stands against CYTK's 80.46% and IONS's 98.98%. Such benchmarking helps identify whether Repligen Corporation is trading at a premium or discount relative to its financial performance.

Repligen has shown consistent revenue growth, with Q2 2026 revenue at $204.13 million, reflecting a 25.01% increase over the last 20 days. The gross margin is strong at 53.91%, indicating effective cost management and profitability.